The Cyclooxigenase-2 Inhibitor Parecoxib Prevents Epidermal Dysplasia in HPV16-Transgenic Mice: Efficacy and Safety Observations
Authors:
- Tiago FerreiraTFTiago Ferreira
- Sandra CamposSCSandra Campos
- Mónica G. SilvaMSMónica G. Silva
- Rita RibeiroRRRita Ribeiro
- Susana SantosSSSusana Santos
- José AlmeidaJAJosé Almeida
- Maria João PiresMPMaria João Pires
- Rui Miguel Gil da CostaRui Miguel Gil da Costa
- Cláudia CórdovaCCCláudia Córdova
- António NogueiraAntónio Nogueira
- Maria João NeuparthMNMaria João Neuparth
- Rui MedeirosRui Medeiros
Open Access
- 10 August 2019
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (16) , 3902
Abstract
Carcinogenesis induced by high-risk human papillomavirus (HPV) involves inflammatory phenomena, partially mediated by cyclooxigenase-2. In pre-clinical models of HPV-induced cancer, cyclooxygenase-2 inhibitors have shown significant efficacy, but also considerable toxicity. This study addresses the chemopreventive effect and hepatic toxicity of a specific cyclooxigensase-2 inhibitor, parecoxib, in HPV16-transgenic mice. Forty-three 20 weeks-old female mice were divided into four groups: I (HPV16−/−, n = 10, parecoxib-treated); II (HPV16−/− n = 11, untreated); III (HPV16+/−, n = 11, parecoxib-treated) and IV (HPV16+/−, n = 11, untreated). Parecoxib (5.0 mg/kg once daily) or vehicle was administered intraperitoneally for 22 consecutive days. Skin lesions were classified histologically. Toxicological endpoints included genotoxic parameters, hepatic oxidative stress, transaminases and histology. Parecoxib completely prevented the onset of epidermal dysplasia in HPV16+/− treated animals (0% versus 64% in HPV16+/− untreated, p = 0.027). Parecoxib decreases lipid peroxidation (LPO) and superoxide dismutase (SOD) activity and increases the GSH:GSSG ratio in HPV16+/− treated animals meaning that oxidative stress is lower. Parecoxib increased genotoxic stress parameters in wild-type and HPV16-transgenic mice, but didn’t modify histological or biochemical hepatic parameters. These results indicate that parecoxib has chemopreventive effects against HPV16-induced lesions while maintaining an acceptable toxicological profile in this model.Keywords
Funding Information
- Portuguese Foundation for Science and Technology (UID/AGR/04033/2019, UID/EQU/00511/2019; UID/CVT/00772/2019; LEPABE-2-ECO-INNOVATION” – NORTE‐01‐0145‐FEDER‐000005 and PEst-OE/QUI/UI0616/2014)
This publication has 50 references indexed in Scilit:
- Evidence-based clinical practice guidelines on management of pain in older peopleAge and Ageing, 2013
- Twelve-gel slide format optimised for comet assay and fluorescent in situ hybridisationToxicology Letters, 2010
- FcRγ Activation Regulates Inflammation-Associated Squamous CarcinogenesisCancer Cell, 2010
- DNA oxidation: Investigating its key role in environmental mutagenesis with the comet assayMutation Research - Genetic Toxicology and Environmental Mutagenesis, 2009
- Evidence for oxidative stress in lens epithelial cells in pseudoexfoliation syndromeEye, 2006
- Pharmacological profile of parecoxib: a novel, potent injectable selective cyclooxygenase-2 inhibitorEuropean Journal of Pharmacology, 2004
- NSAID-Related Psychiatric Adverse EventsDrugs, 2004
- Inflammation and cancerNature, 2002
- Human Papillomavirus Infection as a Risk Factor for Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2001
- Glutathione Transferase Activities and Herbicide Selectivity in Maize and Associated Weed SpeciesPesticide Science, 1996